Alnylam Pharmaceuticals, Inc. (FRA:DUL)
Germany
· Delayed Price · Currency is EUR 393.40
-3.80 (-0.96%)
At close: Dec 5, 2025
Revenue
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2013 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2013 - 2020 |
| AMVUTTRA Revenue | 1.77B | 970.45M |
Log In |
Log In |
Log In | Upgrade
|
| ONPATTRO Revenue | 197.21M | 252.86M |
Log In |
Log In |
Log In | Upgrade
|
| GIVLAARI Revenue | 286.34M | 255.87M |
Log In |
Log In |
Log In | Upgrade
|
| OXLUMO Revenue | 185.36M | 167.05M |
Log In |
Log In |
Log In | Upgrade
|
| Total Product Revenue | 2.44B | 1.65B |
Log In |
Log In |
Log In | Upgrade
|
| Roche - Collaboration Revenue | 373.94M | 119.49M |
Log In |
Log In |
Log In | Upgrade
|
| Regeneron Pharmaceuticals - Collaboration Revenue | 136.78M | 302.80M |
Log In |
Log In |
Log In | Upgrade
|
| Novartis AG - Collaboration Revenue | - | 79.76M |
Log In |
Log In |
Log In | Upgrade
|
| Vir Biotechnology - Collaboration Revenue | - | - |
Log In |
Log In |
Log In | Upgrade
|
| Other - Collaboration Revenue (Pre-FY2023) | - | - |
Log In |
Log In |
Log In | Upgrade
|
| Other - Collaboration Revenue (Post-FY2022) | 48.65M | 8.18M |
Log In |
Log In |
Log In | Upgrade
|
| Total Collaboration Revenue | 619.37M | 510.22M |
Log In |
Log In |
Log In | Upgrade
|
| Royalty Revenue | 148.04M | 91.79M |
Log In |
Log In |
Log In | Upgrade
|
| Revenue (Other) | -559.37M | -510.22M |
Log In |
Log In |
Log In | Upgrade
|
| Revenue (Total) | 3.21B | 2.25B |
Log In |
Log In |
Log In | Upgrade
|